Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Class 2, Grade 2019, Medical College of Qingdao University, Qingdao, 266003, China.
Int Orthop. 2023 Jun;47(6):1493-1510. doi: 10.1007/s00264-023-05753-6. Epub 2023 Mar 10.
Total ankle replacement (TAR) or ankle arthrodesis (AA) is the main surgical treatment for end-stage ankle osteoarthritis. However, the therapeutic effect of the two surgical procedures at different follow-up times remains controversial. The purpose of this meta-analysis is to compare the short-term, medium-term, and long-term safety and efficiency of the two modern surgical treatments.
We conducted a comprehensive search in PubMed, EMBASE, Cochrane library databases, Web of Science, and Scopus. The main results were the patient's reported outcome measure (PROM) score, satisfaction, complications, reoperation, and surgery success rate. Different follow-up times and implant designs were used to evaluate the source of heterogeneity. We used a fixed effects model for meta-analysis and I statistic for evaluating heterogeneity.
Thirty-seven comparative studies were included. In the short term, TAR significantly improved clinical scores (AOFAS score: WMD = 7.07, 95% Cl: 0.41-13.74, I = 0.0%; SF-36 PCS score: WMD = 2.40, 95% Cl: 2.22-2.58, I = 0.0%; SF-36 MCS score: WMD = 0.40, 95% Cl: 0.22-0.57, I = 0.0%; VAS for pain: WMD = - 0.50, 95% Cl: - 0.56-0.44, I = 44.3%) and had the lower incidence of revision (RR = 0.43, 95% CI: 0.23-0.81, I = 0.0%) and complications (RR = 0.67, 95% Cl: 0.50-0.90, I = 0.0%). In the medium term, there were still higher improvements in both the clinical scores (SF-36 PCS score: WMD = 1.57, 95% Cl: 1.36-1.78, I = 20.9%; SF-36 MCS score: WMD = 0.81, 95% Cl: 0.63-0.99, I = 48.8%) and the patient satisfaction (RR = 1.24, 95% Cl: 1.08-1.41, I = 12.1%) in the TAR group, but its total complications rate (RR = 1.84, 95% Cl: 1.26-2.68, I = 14.9%) and revision rate (RR = 1.58, 95% CI: 1.17-2.14, I = 84.6%) were significantly higher than that of the AA group. In the long term, there was no significant difference in clinical score and satisfaction, and a higher incidence of revision (RR = 2.32, 95% Cl: 1.70-3.16, I = 0.0%) and complications (RR = 3.18, 95% Cl: 1.69-5.99, I = 0.0%) was observed in TAR than in AA. The result of the third-generation design subgroup was consistent with that of the above pooled results.
TAR had advantages over AA in the short term due to better performance in terms of PROMs, complications, and reoperation rates, but its complications become a disadvantage in the medium term. In the long term, AA seems to be favored because of lower complications and revision rates, although there is no difference in clinical scores.
全踝关节置换术(TAR)或踝关节融合术(AA)是治疗晚期踝关节骨关节炎的主要手术方法。然而,两种手术在不同随访时间的治疗效果仍存在争议。本荟萃分析的目的是比较两种现代手术治疗的短期、中期和长期安全性和有效性。
我们在 PubMed、EMBASE、Cochrane 图书馆数据库、Web of Science 和 Scopus 中进行了全面检索。主要结果是患者报告的结局测量(PROM)评分、满意度、并发症、再次手术和手术成功率。使用不同的随访时间和植入物设计来评估异质性的来源。我们使用固定效应模型进行荟萃分析,并用 I 统计量评估异质性。
共纳入 37 项比较研究。在短期随访中,TAR 显著改善了临床评分(AOFAS 评分:WMD=7.07,95% Cl:0.41-13.74,I=0.0%;SF-36 PCS 评分:WMD=2.40,95% Cl:2.22-2.58,I=0.0%;SF-36 MCS 评分:WMD=0.40,95% Cl:0.22-0.57,I=0.0%;疼痛 VAS 评分:WMD=-0.50,95% Cl:-0.56-0.44,I=44.3%),并且降低了翻修率(RR=0.43,95% CI:0.23-0.81,I=0.0%)和并发症发生率(RR=0.67,95% Cl:0.50-0.90,I=0.0%)。在中期随访中,TAR 组在临床评分(SF-36 PCS 评分:WMD=1.57,95% Cl:1.36-1.78,I=20.9%;SF-36 MCS 评分:WMD=0.81,95% Cl:0.63-0.99,I=48.8%)和患者满意度(RR=1.24,95% Cl:1.08-1.41,I=12.1%)方面仍有更高的改善,但总并发症发生率(RR=1.84,95% Cl:1.26-2.68,I=14.9%)和翻修率(RR=1.58,95% CI:1.17-2.14,I=84.6%)明显高于 AA 组。在长期随访中,TAR 组与 AA 组在临床评分和满意度方面无显著差异,但 TAR 组的翻修率(RR=2.32,95% Cl:1.70-3.16,I=0.0%)和并发症发生率(RR=3.18,95% Cl:1.69-5.99,I=0.0%)更高。第三代设计亚组的结果与上述汇总结果一致。
由于在 PROMs、并发症和再次手术率方面表现更好,TAR 在短期随访中优于 AA,但在中期随访中,其并发症成为劣势。在长期随访中,尽管临床评分无差异,但 AA 似乎因较低的并发症和翻修率而更受青睐。